Dr. Sangro Discusses Safety Profile of Nivolumab in HCC | OncLive

Dr. Sangro Discusses Safety Profile of Nivolumab in HCC

April 25, 2017

Bruno Sangro, MD, PhD, head of Hepatology Unit, Internal Medicine Department, Clinica Universidad de Navarra, discusses the safety profile of nivolumab (Opdivo) in advanced hepatocellular carcinoma (HCC).

Bruno Sangro, MD, PhD, head of Hepatology Unit, Internal Medicine Department, Clinica Universidad de Navarra, discusses the safety profile of nivolumab (Opdivo) in advanced hepatocellular carcinoma (HCC).

In the CheckMate-040 trial, the PD-1 immune checkpoint inhibitor nivolumab was evaluated in patients with advanced HCC. This was the first time any PD-1 inhibitor was tested in this population, says Sangro.

Nivolumab was found to have a very similar profile to its application in other tumor types, showing very few adverse events. This was found in patients without viral infections as well as patients who have hepatitis B and hepatitis C.


x